Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

Understanding the mechanisms of SGLT inhibition in heart failure and diabetes
10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
  • Overview

    Naveed Sattar summarizes the findings of the EMPA-REG Outcome trial, and what this tells us about potential mechanisms that led to the observed CV benefit with the SGTL2 inhibitor empagliflozin.

  • Educational information

    This lecture by prof Naveed Sattar was part of a CME accredited symposium: Contemporary management of a patient with Heart Failure and diabetes: Implications from recent trials?' held at ESC Heart Failure 2018 in Vienna, Austria.

  • Faculty

    Naveed Sattar , MD is Professor of Metabolic Medicine, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease.

  • Disclosures

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

  • Funding

    Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free